Targeting IGHV1-69: A Promising Drug Pathway (G28461)

Target Name: IGHV1-69

NCBI ID: G28461

IGHV1-69

Other Name(s): IGHV1E | IGHV169 | Immunoglobulin heavy variable 1-69 | immunoglobulin heavy variable 1-69 | IGHV1-E

Targeting IGHV1-69: A Promising Drug Pathway

IGHV1-69, also known as IGHV1-69, is a type of human interleukin-gene 1 (IL-1) receptor that is expressed in various tissues throughout the body, including the immune system, skin, and hair. It is a protein that is composed of two subunits, IGHV1 and IGHV2, which are held together by a disulfide bond.

The IGHV1-69 receptor is involved in the immune response, as it is a key regulator of the activation and proliferation of natural killer cells, which are a crucial part of the immune system. Natural killer cells are responsible for detecting and destroying infected or mutated cells in the body, and they play a crucial role in fighting off viruses, bacteria, and other pathogens.

One of the unique features of the IGHV1-69 receptor is its ability to self-clearer, which means that it can remove itself from the body without any harmful effects. This property makes it an attractive drug target, as researchers believe that targeting the IGHV1 -69 receptor may be a safe and effective way to treat a variety of diseases.

One of the key challenges in targeting the IGHV1-69 receptor is its relatively high expression level, which makes it difficult to block. However, researchers have been able to develop small molecules that can inhibit the activity of the IGHV1-69 receptor, providing some insight into its potential as a drug target.

One of the most promising small molecules that have been identified as potential IGHV1-69 receptor inhibitors is a compound called BAY 94-9343. This compound was synthesized by researchers at the University of California, San Diego and has been shown to inhibit the activity of the IGHV1-69 receptor in cell experiments.

Another small molecule that is being investigated as a potential IGHV1-69 receptor inhibitor is a compound called CS-5018. This compound was synthesized by researchers at the University of Cambridge and has been shown to inhibit the activity of the IGHV1-69 receptor in cell experiments.

While these small molecules are still in the early stages of research, they provide some hope that targeting the IGHV1-69 receptor may be a viable treatment option for a variety of diseases. Additionally, the self-clearer property of the IGHV1-69 receptor makes it is an attractive target for drug development, as it allows for the safe and effective removal of the receptor from the body after treatment.

In conclusion, IGHV1-69 is a protein that is involved in the immune response and has the potential to be a drug target. Its self-clearer property makes it difficult to target, but small molecules such as BAY 94-9343 and CS-5018 have been shown to inhibit the activity of the IGHV1-69 receptor in cell experiments. Further research is needed to fully understand the potential of IGHV1-69 as a drug target and to develop safe and effective treatments for a variety of diseases.

Protein Name: Immunoglobulin Heavy Variable 1-69

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV1-69 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV1-69 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets